Niagen Bioscience Partners with Mass General Brigham for Large-Scale Healthy Aging Trial — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience has signed a Start-Up Agreement with Mass General Brigham (MGB) to plan a large-scale clinical trial on healthy aging using Niagen (nicotinamide riboside).
The trial will be the largest and most comprehensive study of Niagen to date, focusing on adults aged 50 and older.
Howard Sesso, ScD, MPH, from Brigham and Women’s Hospital, will lead the trial design, incorporating clinical, functional, and wellness outcomes.
The trial aims to evaluate Niagen's long-term effects on major clinical outcomes, biomarkers, and healthy aging metrics.

The big picture

This partnership marks a significant step in validating Niagen as a key player in the healthy aging space. The trial’s design, incorporating both clinical and wellness outcomes, aligns with broader industry trends toward preventive medicine and biomarker-driven research. Success could solidify Niagen’s leadership in NAD+ science, while failure may open opportunities for competitors in the rapidly growing anti-aging market.

What we're watching

Trial Execution: Whether Niagen Bioscience can successfully enroll and retain participants in a large-scale, long-term clinical trial.
Regulatory Approval: The pace at which the trial design and endpoints gain regulatory approval for execution.
Market Positioning: How the trial results will impact Niagen’s market position in the NAD+ supplement category.